Abstract
This study addressed the assumption that rate of onset affects the euphorigenic effects of drugs. Drugs with rapid onset are commonly thought to be more euphorigenic than drugs with slower onset, but this idea has rarely been studied directly. Nine healthy male social drinkers, with no history of drug- or alcohol-related problems, participated in three sessions. On each session they received oral doses of placebo (PLAC), diazepam in a rapid onset condition (FAST), or diazepam in a slow onset condition (SLOW). In the FAST condition, they received a single 20 mg dose, whereas in the SLOW condition they received six 4 mg doses administered at 30-min intervals. Plasma levels of diazepam and desmethyldiazepam, subjective effects (including measures of euphoria), psychomotor performance and vital signs were monitored throughout each session. Although the FAST and SLOW conditions led to similar peak plasma levels of drug, the peak was attained earlier in the FAST condition (61 min versus 220 min). Subjects' scores on a measure of euphoria (MBG scale of the ARCI) were significantly higher in the FAST condition compared to the SLOW and PLAC conditions. Subjects exhibited significantly more behavioral signs of intoxication and greater psychomotor impairment in the FAST condition. Sedative effects of the drug were similar in magnitude, but the effects lasted slightly longer in the FAST condition. On several measures diazepam produced similar effects in the two conditions (e.g., ratings of strength of drug effect). These data provide limited support for the notion that a faster rate of onset of drug effects is associated with greater euphoria.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
American Psychiatric Association (1987) Diagnostic and Statistical Manual of Mental Disorders. American Psychiatric Association, Washington, DC
American Psychiatric Association (1990) Benzodiazepine dependence, toxicity, and abuse: a Task Force Report of the American Psychiatric Association. American Psychiatric Association, Washington, DC
Bertilsson L, Henthorn TK, Sanz E, Tybring G, Säwe J, Villén T (1989) Importance of genetic factors in the regulation of diazepam metabolism: relationship toS-mephenytoin, but not debrisoquin, hydroxylation phenotype. Clin Pharmacol Ther 45:348–355
Bliding A (1974) Effects of different rates of absorption of two benzodiazepines on subjective and objective parameters. Eur J Clin Pharmacol 7:201–211
Busto U, Sellers EM (1986) Pharmacokinetic determinants of drug abuse and dependence. Clin Pharmacokinet 11:144–153
Derogatis L (1983) SCL-90-R Manual-II. Clinical Psychometric Research, Towson, MD
de Wit H (1991) Diazepam preference in males with and without an alcoholic first-degree relative. Alcohol Clin Exp Res 15:593–600
de Wit H, Griffiths RR (1991) Methods of assessing the abuse liability of sedatives in humans. Drug Alcohol Depend 28:83–111
de Wit H, Pierri J, Johanson CE (1989) Reinforcing and subjective effects of diazepam in non-drug-abusing volunteers. Pharmacol Biochem Behav 33:205–213
de Wit H, Bodker B, Ambre J (1992) Rate of increase of plasma drug level influences subjective response in humans. Psychopharmacology 107:352–358
Farré M, Camí J (1991) Pharmacokinetic considerations in abuse liability evaluation. Br J Addict 86:1601–1606
Funderburk FR, Griffiths RR, McLeod DR, Bigelow GE, Mackenzie A, Liebson IA, Nemeth-Coslett R (1988) Relative abuse liability of lorazepam and diazepam: an evaluation in “recreational” drug users. Drug Alcohol Depend 22:215–222
Ghoneim MD, Mewaldt SP (1990) Benzodiazepines and human memory: a review. Anesthesiology 72:926–938
Greenblatt DJ, Sethy VH (1990) Benzodiazepine concentrations in brain directly reflect receptor occupancy: studies of diazepam, lorazepam, and oxazepam. Psychopharmacology 102:373–378
Greenblatt DJ, Shader RI (1987) Pharmacokinetics of antianxiety agents. In: Meltzer HY (ed.) Psychopharmacology: The Third Generation of Progress. Raven, New York, pp 1377–1386
Greenblatt DJ, Shader RI, Hermatz JS, Franke K, Koch-Weser J (1977) Absorption rate, blood concentrations, and early response to oral chlordiazepoxide. Am J Psychiatry 134:559–562
Greenblatt DJ, Ochs HR, Lloyd BL (1980) Entry of diazepam and its major metabolite into cerebrospinal fluid. Psychopharmacology 70:89–93
Greenblatt DJ, Arendt RM, Shader RI (1984) Pharmacodynamics of benzodiazepines after single oral doses: kinetic and physiochemical correlates. In: Hindmarch I, Ott H, Roth T (eds) Sleep, benzodiazepines and performance. Springer, Berlin Heidelberg New York, pp 92–97
Greenblatt DJ, Harmatz JS, Friedman H, Locniskar A, Shader RI (1989) A large-sample study of diazepam pharmacokinetics. Ther Drug Monit 11:652–657
Griffiths RR, Wolf B (1990) Relative abuse liability of different benzodiazepines in drug abusers. J Clin Psychopharmacol 10:237–243
Griffiths RR, Bigelow GE, Liebson I, Kaliszak JE (1980) Drug preference in humans: double-blind choice comparison of pentobarbital, diazepam and placebo. J Pharmacol Exp Ther 215:649–661
Griffiths RR, McLeod DR, Bigelow GE, Liebson IA, Roache JD, Nowowieski P (1984) Comparison of diazepam and oxazepam: preference, liking and extent of abuse. J Pharmacol Exp Ther 229:501–508
Jaffe JH (1990) Drug addiction and drug abuse. In: Gilman AG, Rall TW, Nies AS, Taylor P (eds) Goodman and Gilman's The Pharmacological Basis of Therapeutics. Pergamon, New York, pp 522–573
Johanson CE, Uhlenhuth EH (1980) Drug preference and mood in humans: diazepam. Psychopharmacology 71:269–273
Jones DR, Hall SD, Jackson EK, Branch RA, Wilkinson GR (1988) Brain uptake of benzodiazepines: effects of lipophilicity and plasma protein binding. J Pharmacol Exp Ther 245:816–822
Kaplan SA, Jack ML, Alexander K, Weinfeld RE (1973) Pharmacokinetic profile of diazepam in man following single intravenous and oral and chronic oral administrations. J Pharm Sci 62:1789–1796
Martin WR, Sloan JW, Sapira JD, Jasinski DR (1971) Physiologic, subjective and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine and methylphenidate in man. Clin Pharmacol Ther 12:245–258
Mattila M (1988) Acute and subacute effects of diazepam on human performance: comparison of plain tablet and controlled release capsule. Pharmacol Toxicol 63:369–374
McLeod DR, Hoehn-Saric R, Labib AS, Greenblatt DJ (1988) Six weeks of diazepam treatment in normal women. J Clin Psychopharmacol 8:83–99
McNair D, Lorr M, Droppleman L (1971) Profile of mood states (manual). Educational and Industrial Testing Service, San Diego
Parrott AC, Hindmarch I (1980) The Leeds Sleep Evaluation Questionnaire in psychopharmacological investigations — a review. Psychopharmacology 71:173–179
Salonen M, Aantaa E, Aaltonen L, Hovi-Viander M, Kanto J (1986) A comparison of the soft gelatin capsule and the tablet form of temazepam. Acta Pharmacol Toxicol 58:49–54
Tuomainen P (1989) A methodological comparison of two formulations of temazepam in pharmacokinetic and pharmacodynamic aspects. Pharmacol Toxicol 64:28–32
Wechsler D (1958) The measure and appraisal of adult intelligence. Williams and Wilkins, Baltimore
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
de Wit, H., Dudish, S. & Ambre, J. Subjective and behavioral effects of diazepam depend on its rate of onset. Psychopharmacology 112, 324–330 (1993). https://doi.org/10.1007/BF02244928
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02244928